FDA would have the burden of proof in issuing warnings against importation of products by consumers, pharmacies or wholesalers under HR 3240, passed by the House June 28 after the vote on the Medicare drug benefit plan. The bill was sponsored by Rep. Gutknecht (R-Minn.) as a means to address cross-border pricing differences
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
